Synagis (Palivizumab) belongs to the class of medications known as monoclonal antibodies. Antibodies are used to protect people against infections.
Available form
Injectable
Dosage
Manufacturer
Abbvie Corporation
We won't bore you with the details, but Health Canada requires you to sign in.
By proceeding you agree to our Terms of Use & Privacy Policy
The usual recommended dose is 15 mg per kilogram of body weight, based on the child's body weight. It is given as an injection into a muscle (usually the thigh muscle) once a month during the RSV season (i.e., the times of the year when the risk of RSV is high in your community).
Many things can affect the dose of a medication that a person needs, such as body weight, other medical conditions, and other medications. If your doctor has recommended a dose different from the ones listed here, do not change the way that you are taking the medication without consulting your doctor.
The RSV season often starts in the fall and continues until spring, although it can also occur at other times of the year. If possible, the first injection should be given before the RSV season starts. The injection will be given by a qualified health care professional.
It is important that Synagis (Palivizumab) be given exactly as recommended by your doctor. If your child misses an appointment to receive Synagis (Palivizumab), contact your doctor as soon as possible to reschedule your appointment. Each injection protects your child for about one month, so it is important to continue regular monthly injections during the RSV season, as recommended by your doctor.
If you are responsible for bringing Synagis (Palivizumab) to the appointment, store this medication in the refrigerator, do not freeze, and keep out of the reach of children.
Do not dispose of medications in wastewater (e.g. down the sink or in the toilet) or in household garbage. Ask your pharmacist how to dispose of medications that are no longer needed or have expired.
Many medications can cause side effects. A side effect is an unwanted response to a medication when it is taken in normal doses. Side effects can be mild or severe, temporary or permanent.
The side effects listed below are not experienced by everyone who takes Synagis (Palivizumab). If you are concerned about side effects, discuss the risks and benefits of Synagis (Palivizumab) with your doctor.
The following side effects have been reported by at least 1% of people taking this medication. Many of these side effects can be managed, and some may go away on their own over time.
Contact your doctor if you experience these side effects and they are severe or bothersome. Your pharmacist may be able to advise you on managing side effects.
Although most of these side effects listed below don't happen very often, they could lead to serious problems if you do not check with your doctor or seek medical attention.
Check with your doctor as soon as possible if any of the following side effects occur:
Stop taking the medication and seek immediate medical attention if any of the following occur:
Some people may experience side effects other than those listed. Check with your doctor if you notice any symptom that worries you while you are taking Synagis (Palivizumab).
Lyophilized Powder
Synagis Lyophilized Powder is no longer being manufactured for sale in Canada and is no longer available under any brand names. This product information is being kept available for reference purposes only. If you are using Synagis (Palivizumab), speak with your doctor or pharmacist for information about your treatment options.
Solution for Injection
50 mg
Each 0.5 ml of solution for injection contains Synagis (Palivizumab) 50 mg. Nonmedicinal ingredients: chloride, glycine, histidine, and water for injection
100 mg
Each mL of solution for injection contains Synagis (Palivizumab) 100 mg. Nonmedicinal ingredients: chloride, glycine, histidine, and water for injection.
Do not take Synagis (Palivizumab) if you:
Specific drug interaction studies have not been conducted with Synagis (Palivizumab). However, since Synagis (Palivizumab) is specific for RSV, it is not expected to interfere with the immune response to vaccines, including live viral vaccines.
Tell your doctor or prescriber about all prescription, over-the-counter (non-prescription), and herbal medications your child is taking. Also tell them about any supplements your child takes. Depending on your child's specific circumstances, your doctor may want your child to:
An interaction between two medications does not always mean that you must stop taking one of them. Speak to your doctor about how any drug interactions are being managed or should be managed.
Before you begin using a medication, be sure to inform your doctor of any medical conditions or Allergies your child may have, any medications your child is taking, and any other significant facts about your child's health. These factors may affect how they should use Synagis (Palivizumab).
Acute infection or fever: A Synagis (Palivizumab) injection may be delayed if your child is feeling unwell or has a fever due to an infection.
Allergic reactions: Very rarely, Synagis (Palivizumab) may cause a serious allergic reaction. If your child develops hives, difficulty breathing, or swelling of the face or throat, seek medical attention immediately.
Bleeding disorders: Synagis (Palivizumab) is given by injection into the muscle. This can cause bleeding at the injection site when the child receiving the injection has a bleeding disorder. If your child has a bleeding disorder, discuss with their doctor how Synagis (Palivizumab) may affect their medical condition, how their medical condition may affect the dosing and effectiveness of Synagis (Palivizumab), and whether any special monitoring is needed.
The doctor should monitor your child if your child has a bleeding disorder and is receiving Synagis (Palivizumab).
Use by adults: Synagis (Palivizumab) is intended for use by infants and children. The safety and effectiveness of Synagis (Palivizumab) for use by adults have not been established.
Pregnancy: Synagis (Palivizumab) is not intended for adult use. Its safety and effectiveness when used by pregnant women are not known.
Breast-feeding: Synagis (Palivizumab) is not intended for adult use. Its safety and effectiveness when used by breast-feeding women are not known.
price lookup
Total no. of dose(s)
Manufacturer
Insurance coverage
Dosage
*Actual pricing may differ. Medication is only available by prescription. The cost may be subsidised by your provincial or private health plan.
price details
Total (CAD)
--*
Drug info not available
It’s like having us in your pocket, putting you first in every interaction.
Your medication is delivered to you at no added cost.
Call, text, email—whatever works for you. We’re humans, ready to help.
Discreet with real-time updates. Go about your day, your meds are on the way.
Your region
,
Pocketpills is licensed by
Accreditation No
#
Pharmacy Manager
2025 Pocketpills
Pocketpills is not a pharmacy
or a drug manufacturer